Wang Hui, CEO of Advanced BioMedical Technology Inc.. Advanced BioMedical Systems commences animal tests with novel patented PA bio-absorbable material Advanced BioMedical Technologies Inc. announced that the business’s subsidiary, Shenzhen Changhua Biomedical Engineering Co., Ltd. , offers signed a cooperative contract with The Initial Affiliated Medical center of Guangdong Pharmaceutical University in Guangzhou. Under this cooperative contract, both celebrations will join efforts in conducting research and animal assessments on Cranio-Maxillofacial Fracture Treatment and Craniofacial Reconstruction making use of ABT-CHANGHUA’s novel patented PA bio-absorbable material. Related StoriesStudy: Post medical center syndrome is significant risk factor for individuals undergoing elective surgeryChildren's Memorial Hermann Hospital offers Halloween protection tipsACC's general public reporting system provides information regarding hospitals' performanceABT-CHANGHUA will make sample PA bio-absorbable miniscrews and plates for analysis and animal test; GDPU Hospital will conduct research and animal testing, and a Stage II clinical trial because of this new indication.Completed in cooperation with Duke-NUS, the drug is likely to enter the scientific trial stage around middle of 2014. Meanwhile, ETC is certainly in the first stages of developing a flu vaccine with A*STAR's Indication , D3 , Duke-NUS, DSO and many private companies. By the center of 2013, the consortium can determine if it’s ready for Stage I scientific trials for proof-of-concept in humans. If successful, this flu vaccine will play a crucial role in national preparedness as it will ensure that Singaporeans will have access to the vaccine in situations of a flu pandemic. Professor Matter has lived in Singapore for the past nine-and-a-half years. To joining ETC as CEO Prior, Professor Matter was the director of the Novartis Institute of Tropical Disease since 2004.